Amundi Purchases 11,634 Shares of Artivion, Inc. (NYSE:AORT)

Amundi boosted its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 174.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,288 shares of the company's stock after buying an additional 11,634 shares during the quarter. Amundi's holdings in Artivion were worth $553,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of AORT. Quest Partners LLC grew its stake in shares of Artivion by 2,481,700.0% in the 3rd quarter. Quest Partners LLC now owns 24,818 shares of the company's stock worth $661,000 after purchasing an additional 24,817 shares during the last quarter. Intech Investment Management LLC lifted its position in shares of Artivion by 6.6% in the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company's stock worth $280,000 after purchasing an additional 653 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Artivion by 28.1% during the third quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company's stock valued at $522,000 after purchasing an additional 4,295 shares in the last quarter. FMR LLC increased its stake in Artivion by 28.0% in the 3rd quarter. FMR LLC now owns 115,184 shares of the company's stock valued at $3,066,000 after buying an additional 25,176 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Artivion by 543.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company's stock worth $761,000 after buying an additional 24,130 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have weighed in on AORT shares. Needham & Company LLC cut their target price on Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Stifel Nicolaus decreased their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research report on Tuesday, February 25th. Finally, JMP Securities restated a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artivion has an average rating of "Buy" and a consensus price target of $31.40.

Artivion Trading Up 2.3 %

Shares of Artivion stock traded up $0.56 during trading hours on Monday, hitting $24.99. The company's stock had a trading volume of 468,205 shares, compared to its average volume of 266,064. The company has a market capitalization of $1.05 billion, a PE ratio of -1,249.25 and a beta of 1.79. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a 50 day moving average of $28.14 and a 200 day moving average of $27.66. Artivion, Inc. has a 12 month low of $19.36 and a 12 month high of $32.33.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Activity

In other news, insider John E. Davis sold 15,100 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $356,511.00. Following the completion of the transaction, the insider now owns 208,778 shares of the company's stock, valued at approximately $4,929,248.58. This represents a 6.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the sale, the chief executive officer now directly owns 663,882 shares in the company, valued at $18,130,617.42. This trade represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,799 shares of company stock valued at $2,356,223 in the last quarter. Company insiders own 8.10% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.